A

Alumis Inc.
D

ALMS

23.960
USD
0.94
(4.08%)
مغلق
حجم التداول
0
الربح لكل سهم
-3
العائد الربحي
-
P/E
-6
حجم السوق
3,101,268,326
المقالات
المزيد

العنوان: Alumis Inc.

القطاع: الرعاية الصحية
الصناعة: Biotechnology
Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005,a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.